FDA advisers suggest covering highly spreadable subclade k variant in flu vaccines

By Admin

14 Mar, 2026

The fight against seasonal influenza may soon take a new direction. A U.S. Food and Drug Administration (FDA) advisory committee has recommended that upcoming flu vaccines include protection against a rapidly spreading variant known as subclade K. The recommendation comes after experts observed that the current flu season saw lower vaccine effectiveness and an unusual surge in infections across several regions of the world.

This proposed update could influence the flu vaccine formulation for the upcoming fall season, aiming to improve protection against one of the dominant strains circulating in the Northern Hemisphere.

FDA Advisory Committee Recommends Including Subclade K

During a recent meeting, an FDA advisory panel voted to recommend the inclusion of subclade K, a viral strain within the H3N2 influenza family, in future influenza vaccines. The decision aligns with guidance from the World Health Organization (WHO), which also suggested targeting the variant due to its growing presence in global flu cases.

Experts believe this variant may be one reason the 2025–2026 flu vaccines were less effective than in previous years. Scientists typically decide the composition of seasonal flu vaccines several months in advance because vaccine manufacturing takes around six months. This early decision-making helps ensure enough doses are available before flu season begins.

Arnold Monto, an epidemiologist at the University of Michigan and acting chair of the Vaccines and Related Biological Products Advisory Committee, explained the complexity of selecting flu strains. According to him, strain selection involves both scientific analysis and a degree of unpredictability.

Flu Vaccine Effectiveness This Season

According to the Centers for Disease Control and Prevention (CDC), the effectiveness of this season’s influenza vaccine was lower than in recent years but still offered meaningful protection.

The CDC reported in its Morbidity and Mortality Weekly Report (MMWR) that vaccine effectiveness ranged between:

• 38%–41% for preventing outpatient visits among children and adolescents
  
  

• 41% effectiveness in preventing hospitalizations in younger populations
  
  

• 22%–34% effectiveness against outpatient visits among adults
  
  

• 30% effectiveness in preventing influenza-related hospitalization in adults
  
  

Despite these relatively lower percentages, public health officials emphasized that vaccination remains one of the most effective tools against severe flu outcomes.

During the previous flu season, vaccines prevented an estimated:

• 5 million medical visits
  
  

• 180,000 hospitalizations
  
  

• 12,000 deaths
  
  

Meanwhile, between October 1 and February 28, the CDC estimates that influenza caused at least 26 million illnesses, 340,000 hospitalizations, and 21,000 deaths in the United States.

Why Subclade K Is Concerning

Subclade K is a newly emerged subgroup of the H3N2 influenza strain, a virus that has circulated among humans for decades. However, recent mutations appear to have increased its ability to spread.

Dr. Lisa Grohskopf, a medical officer in the CDC’s Influenza Division, told the advisory committee that subclade K has become the dominant flu variant in the Northern Hemisphere this year.

The variant has been linked to early and intense flu surges in several countries, including the United States, Japan, the United Kingdom, and parts of Europe.

Health officials in the United Kingdom, reviewing preliminary surveillance data, suggested the variant may spread more easily than other flu strains, contributing to higher hospitalization rates and increased positive flu tests in hospitals.

Is Subclade K More Dangerous?

While subclade K appears to spread more easily, experts say there is no clear evidence that it causes more severe illness than other influenza variants.

Dr. Scott Roberts, an infectious disease specialist at Yale Medicine, explained that the term “super flu” being used in some reports mainly reflects the large number of infections and hospital admissions, not necessarily increased severity.

According to Roberts, the rise in cases is more likely due to the virus’s mutations and increased transmissibility, rather than the strain causing more serious disease.

The Challenge of Predicting Flu Strains

Choosing which strains to include in flu vaccines is a complex process. Viruses constantly mutate, making it difficult to predict which variants will dominate months later when flu season arrives.

The University of Minnesota’s Center for Infectious Disease Research and Policy notes that strain selection involves analyzing global surveillance data and trends, but there is no guarantee that the chosen variants will be the same ones circulating in the next flu season.

This uncertainty is why health authorities review and update vaccine formulations every year.

Why Flu Vaccination Still Matters

Even with moderate effectiveness, influenza vaccination remains a critical public health tool. Vaccines reduce the risk of severe illness, hospitalizations, and deaths, particularly among children, older adults, and people with underlying health conditions.

Health experts continue to encourage annual flu shots as the best available protection against the virus, especially when new variants like subclade K emerge.

✅ Conclusion

The FDA advisory committee’s recommendation to include subclade K in upcoming flu vaccines reflects ongoing efforts to keep influenza protection aligned with evolving viral strains. While predicting the exact course of future flu seasons remains challenging, updating vaccine formulations improves the chances of reducing infections and severe outcomes.

As scientists continue monitoring influenza mutations worldwide, public health officials emphasize that annual vaccination remains one of the most effective strategies for protecting individuals and communities from seasonal flu.